Arctic Bioscience AS (ABS.OL) is a clinical-stage biotechnology company that develops, manufactures and commercializes pharmaceutical and nutraceutical products based on bioactive marine membrane lipids derived primarily from Norwegian spring-spawning herring roe sourced through MSC-certified fisheries; its pharmaceutical pipeline centers on HRO350, an investigational oral drug candidate for mild-to-moderate psoriasis targeting a large global market with unmet needs, while nutraceuticals include high-DHA Omega-3 phospholipid extracts, herring caviar oils and proteins sold globally in bulk B2B formats or as finished goods under the Romega brand for premium consumer applications. Founded in 2011 and headquartered in Ørsta on the northwest coast of Norway with additional offices in Oslo Science Park and international presence in the US and Canada, the company operates in the health and life sciences sector serving healthcare providers, nutraceutical manufacturers and end consumers with innovative marine-derived therapies for autoimmune disorders and premium omega-3 supplements. In January 2025, Arctic Bioscience secured NOK 30 million in long-term funding comprising a NOK 15 million loan from Innovation Norway guaranteed by the European Investment Fund and a NOK 15 million convertible loan from existing shareholders and new Icelandic investors to achieve cash positivity amid 30% year-over-year sales growth in 2024 and cost reduction measures; the HeROPA Phase IIb trial for HRO350 advances toward 12-month readout by end of Q1 2026 with potential Phase III partnerships pending positive results, building on the 2023 acquisition of Arctic Algae AS to enhance micro-algae extraction capabilities for expanded marine lipid applications.